MRM based validation of protein biomarkers across different grades of glioma tissues

Gliomas are tumors originating from the glial cells, accounting for ~28% of all CNS tumors. They are characterized by rapid proliferation rate and poor prognosis. Around 80% of the gliomas are malignant with a median survival of about 10-12 months. Based on the immunohistology, microscopic properties and mutational status, gliomas are classified into four grades. The current study was performed to develop MRM assays for validating candidate proteins arising from previous shotgun proteomics experiment and holds potential to distinguish between different grades of gliomas.

Content Type:
Document Number:
Product Type:
Liquid Chromatograph-Mass Spectrometry, Mass Spectrometry
glioma tissues, Pharmaceutical, Life Science, LCMS-8050
File Name:
File Size:

Free Download

For Research Use Only. Not for use in diagnostic procedures.

This page may contain references to products that are not available in your country. Please contact us to check the availability of these products in your country.

Top of This Page